Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23098991 | 0.99 | ALDH1A1 (0.49) | ALDH1A1TSHRPRMT5WDR77HDAC6 | |
| SCHEMBL23087933 | 0.97 | PRMT5 (0.45) | ALDH1A1TSHRPRMT5WDR77HDAC6 | |
| SCHEMBL23087794 | 0.94 | PRMT5 (0.43) | ALDH1A1TSHRPRMT5WDR77HDAC6 | |
| SCHEMBL20596105 | 0.80 | CREBBP (0.34) | PRMT5WDR77 | |
| SCHEMBL23099048 | 0.79 | CREBBP (0.46) | ALDH1A1PRMT5WDR77HDAC6KMT2A | |
| SCHEMBL23087291 | 0.75 | PRMT5 (0.47) | ALDH1A1TSHRPRMT5WDR77KMT2A | |
| SCHEMBL23087798 | 0.73 | GRM5 (0.49) | ALDH1A1TSHRPRMT5WDR77LMNA | |
| SCHEMBL25061821 | 0.70 | FAAH (0.33) | — | |
| SCHEMBL23087887 | 0.69 | PRMT5 (0.39) | PRMT5WDR77 | |
| SCHEMBL30929928 | 0.68 | ALDH1A1 (0.95) | ALDH1A1TSHRKMT2AFASNCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| WO-2021050915-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ALDH1A1 4000/4885TSHR 3841/4885PRMT5 1/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | ALDH1A1 3367/4885TSHR 3731/4885PRMT5 2/4885 |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | ALDH1A1 4216/4885TSHR 3640/4885PRMT5 1/4885 |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | ALDH1A1 4216/4885TSHR 3640/4885PRMT5 1/4885 |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ALDH1A1 4000/4885TSHR 3841/4885PRMT5 1/4885 |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | ALDH1A1 4216/4885TSHR 3640/4885PRMT5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.